← Back to Search

Monoclonal Antibodies

BMS-986403 for Chronic B-Cell Leukemia

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years after bms-986403 infusion
Awards & highlights

Study Summary

This trial is testing a new drug for people with leukemia or lymphoma who have not responded to other treatments.

Eligible Conditions
  • Chronic B-Cell Leukemia
  • Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years after bms-986403 infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years after bms-986403 infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum-tolerated dose (MTD) based on the incidence of DLTs that occur during the DLT evaluation period
Number of participants with adverse events (AEs)
Number of participants with clinical laboratory abnormalities
+3 more
Secondary outcome measures
Complete remission rate (CRR)
Duration of complete remission (DOCR)
Duration of response (DOR)
+8 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: BMS-986403 + Fludarabine + CyclophosphamideExperimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fludarabine
2012
Completed Phase 3
~1080
Cyclophosphamide
1995
Completed Phase 3
~3770

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,650 Previous Clinical Trials
4,130,827 Total Patients Enrolled
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top